Trials / Completed
CompletedNCT00219167
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 355 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2005-09-22
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00219167. Inclusion in this directory is not an endorsement.